A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Clinical trial NCT05141747 · UNKNOWN

Trial details

NCT number: NCT05141747
Sponsor: Shanghai Miracogen Inc.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Gastric Cancer Metastatic HER2 Positive Gastroesophageal Junction Cancer

Start date: 2022-01-19
Primary completion: 2023-12-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.